Document is current
Any future updates will be listed below
-
Authors
Ahrenfeldt, Johanne https://orcid.org/0000-0001-9175-0373
Jespersen, Jesper https://orcid.org/0009-0001-7516-403X
Lyngstrand, Jens Ejrnæs https://orcid.org/0009-0004-0086-5650
Iisager, Laura https://orcid.org/0000-0002-5704-0586
Keller, Anna Krarup https://orcid.org/0000-0002-9109-5521
Fristrup, Niels https://orcid.org/0009-0006-4442-0535
Laurberg, Tinne https://orcid.org/0000-0002-7555-2665
Lyskjær, Iben https://orcid.org/0000-0003-3446-1182
-
Funding
Funding for this research was provided by:
Lundbeck Foundation (R413-2022-606)
Købmand Inger Bonnens Fond
Lizzi og Mogens Staal Fonden
Fabrikant Einar Willumsens Mindelegat
Aarhus Universitet
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 11 April 2025
First Online: 14 May 2025
Declarations
:
: NF has performed consulting for Pfizer, Eisai, MSD, BMS, and has received speaker honoraria from AstraZeneca, BMS, MSD. The other authors declare no conflicts of interest.
